DeCode, Spending More on Clinical Trials, Reports Ballooning Losses, Smaller Revenues in Q3 | GenomeWeb

NEW YORK, Nov. 3 (GenomeWeb News) - DeCode Genetics yesterday reported reduced revenues and a gaping net loss for the third quarter of the year, mainly related to higher R&D costs for its drug-development programs.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.